A group of scientists have questioned the reliability of data published by Russian scientists on early clinical trials of its 'Sputnik V' coronavirus vaccine, with one telling CNBC that Russia needs to explain and clarify its results.
In an open letter to the editor of The Lancet medical journal, in which Russia's Gamalaya Research Institute of Epidemiology and Microbiology published early-stage trial results of its coronavirus vaccine last Friday, a group of scientists said the data published was incomplete and had shown some "unlikely patterns."
They said the results showed that groups of participants had reported identical antibody levels at different points in the study. There are 27 signatories of the letter so far — predominantly scientists based in Europe but also including several in the U.S. and Asia. "While potentially of great interest, the research described in the article published by Lancet presents several different points of concern,". Bucci was also one of the original authors and signatories of the open letter to the editor of The Lancet.
The Gamaleya Institute was not immediately available to comment when contacted by CNBC on Thursday. Earlier, however, it rebuffed the critique of its vaccine, with Denis Logunov, a deputy director at the institute, issuing a statement in which he said "the published results are authentic and accurate and were examined by five reviewers at The Lancet," Reuters reported.
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Some scientists spot 'unlikely' patterns in Russia vaccine data: letterTwenty-six scientists, most of them working at universities in Italy, have signed an open letter questioning the reliability of the data presented in the early-stage trial results of the Russian COVID-19 vaccine, named 'Sputnik-V'.
Read more »
Some scientists spot 'unlikely' patterns in Russia vaccine data: letterTwenty-six scientists, most of them working at universities in Italy, have signed an open letter questioning the reliability of the data presented in the early-stage trial results of the Russian COVID-19 vaccine, named 'Sputnik-V'.
Read more »
China's CanSino defends coronavirus vaccine candidate after experts cast doubtChina's CanSino Biologics Inc said on Wednesday that expert opinion on its high-profile coronavirus vaccine candidate should not be followed 'blindly' without sufficient clinical trial data.
Read more »
Pause in AstraZeneca vaccine trial not necessarily a setback, says UK health ministerBritain's Health Secretary Matt Hancock said on Wednesday that AstraZeneca's decision to pause its coronavirus vaccine trials was a challenge but would not necessarily set back efforts to develop a vaccine.
Read more »
AstraZeneca Pauses COVID-19 Vaccine Trial Due To Volunteer's IllnessNPR's Noel King talks to Paul Offit of the Vaccine Education Center at Children's Hospital of Philadelphia, about the coronavirus vaccine trial developed by AstraZeneca and the University of Oxford.
Read more »
AstraZeneca suspends leading COVID-19 vaccine trials after a participant's illnessAstraZeneca Plc said it has paused global trials, including large late-stage trials, of its experimental coronavirus vaccine due to an unexplained illness in a study participant.
Read more »